Twelve questions before you book

Vetting an airport-cluster clinic is a different exercise than vetting a central-Seoul senior-physician practice, because the operational compression of the transit window leaves less margin for the slow, conversational consultation that the multi-day Seoul-stay patient enjoys. The transit patient has to make a clinic decision before the flight, with no in-person consultation buffer, on the strength of pre-booking signals that either hold up or do not. This checklist is the editorial framework I use as Ji-Won Choi when I evaluate which airport-cluster clinics meet the standard I would refer a friend to, and which fall short of it. The twelve questions below are the genuine vetting questions a transit patient should put to an airport-cluster clinic before booking — not a marketing checklist, not a hospitality questionnaire, but the operational and clinical disclosures that separate a competent transit-discipline practice from a clinic that has simply hung a near-airport address on a standard aesthetic-clinic operating model. The questions are written for the patient to ask the clinic directly through the messaging channel before booking; the answers should arrive in writing within 12 to 24 hours, and the quality of those answers is itself a vetting signal that is at least as informative as their content. A clinic that takes four days to respond, or that responds with deflective generalities, is communicating something about its transit-patient discipline; a clinic that responds within hours with specific written answers is communicating something else. Both signals matter.

Question 1 — Is the clinic MFDS-supervised for regenerative dermatology, and what does that mean here?

MFDS supervision is the baseline regulatory layer for regenerative dermatology in Korea, and the first vetting question is whether the clinic operates under it. The Ministry of Food and Drug Safety (MFDS) regulates the bio-active products used in exosome IV and microneedling protocols — the exosome vials, growth-factor concentrates, conditioned-media preparations — through a licensing framework that the cell-processing facilities must meet before product can be supplied to clinics. The vetting question is not whether the clinic itself holds an MFDS licence (clinics do not; the products do), but whether the bio-active product the clinic uses comes from an MFDS-licensed cell-processing facility and whether the clinic can produce, on request, the product-lot documentation that ties a given vial back to its licensed manufacturing source. The answer should arrive in writing with the manufacturing-facility name and the product-lot reference; a clinic that cannot produce this documentation is operating outside the editorial standard for regenerative practice. Confirm with the MFDS English portal that the named facility appears in the licensed-manufacturer registry; the public registry is the verification layer the patient can use without Korean-language fluency.

Question 2 — Is the clinic KHIDI-registered as a medical-tourism receiving organisation?

KHIDI — the Korea Health Industry Development Institute — operates the registration framework for medical-tourism receiving organisations under the Ministry of Health and Welfare. The KHIDI registration is the regulatory layer specifically governing international-patient handling: language-coordination standards, complaint-resolution channels, billing-transparency requirements, and the basic dispute-handling pathway available to the international patient. The vetting question is whether the clinic appears in the KHIDI international-medical-services registry, and whether the registration number is visible in writing on the clinic's booking communications. The registration number takes the form A-YYYY-MM-DD-NNNNN (an alphanumeric reference with the date components and a five-digit sequence), and patients should be able to verify the number against the KHIDI public registry. A clinic without a KHIDI registration is operating outside the medical-tourism regulatory framework even if its clinical practice is otherwise compliant; the editorial standard is to book only through KHIDI-registered receiving organisations because the registration is the patient's recourse channel if the post-procedure relationship goes wrong.

Question 3 — Who is the treating physician, and what are their credentials?

The treating physician is the clinical authority in the procedure, and the third vetting question is who that person is by name and what their credentials are. The disclosure should arrive with the physician's full name in roman characters, their Korean medical licence number, their specialty designation (the Korean specialty taxonomy lists Aesthetic Medicine Specialist and Medical Director among others), and the duration of their independent practice in regenerative dermatology. The editorial expectation is a senior physician with at least ten years of independent practice and documented experience with exosome and growth-factor protocols specifically; a junior-trainee or non-specialist physician operating an airport-cluster transit clinic is a substantive vetting concern. The disclosure should not require the patient to ask twice; it should arrive proactively in the booking communications as a matter of standard transit-clinic transparency. Clinics that deflect on this question — citing internal policies, organisational structure, or 'team-based care' that does not name an individual responsible physician — are clinics the editorial recommendation is to choose differently.

Question 4 — What is the bio-active product, and where is it sourced?

The bio-active product is the substantive clinical input, and the fourth vetting question is what the product is and where it comes from. The disclosure should name the manufacturer, the product type (exosome vial, growth-factor concentrate, conditioned-media preparation), and the MFDS licence reference for the manufacturing facility. The editorial standard is single-source product from a named MFDS-licensed cell-processing facility, with the manufacturer's documentation available to the patient on request. Multi-vendor sourcing without clear identification is a vetting concern; sourcing from an unnamed 'cell-therapy supplier' is a vetting concern; product whose manufacturer cannot be verified against the MFDS registry is a vetting concern. Patients should not assume that all airport-cluster clinics are using equivalent product; the bio-active product is the variable that most directly drives the response profile, and a clinic operating with cheaper or less-documented product is delivering a different clinical proposition than a clinic operating with the leading manufacturers.

Question 5 — What protocol depths does the clinic offer in the transit window?

Protocol depth is the operational variable that defines the transit-clinic product, and the fifth vetting question is what depths the clinic offers within a given layover window. The expected disclosure is the standard transit-clinic tier structure: 90-minute IV-only protocol, 4-hour IV-plus-microneedling combined protocol, 8-hour full-course protocol with sequenced energy-based delivery. A clinic that does not offer the full tier range is a clinic with a narrower transit product; this is not necessarily disqualifying (a clinic specialising in the 4-hour middle tier can be operationally excellent) but it is a fact the patient should know before booking. More substantively, a clinic that pressures the transit patient toward a higher tier than the layover window genuinely supports — an 8-hour full-course protocol for a 6-hour layover — is a clinic that has departed from transit discipline, and the editorial recommendation is to choose differently. The right answer to 'what protocols do you offer?' is a written tier menu with chair-time, included add-ons, and pricing in KRW; an answer that requires a phone call or that defers to in-person consultation is a clinic that is not transit-equipped.

Question 6 — What is the all-in package price in KRW, with line items?

Pricing transparency is a vetting signal in itself, and the sixth vetting question is the all-in package price in KRW with line items separately identified: procedure cost, bio-active product, topical anaesthesia, post-procedure regimen, airport pickup and return transfer, any remote-review or messaging-channel commitment. The editorial expectation is a single all-in figure in KRW with the line items broken out for transparency, and the line items should be free of surprise charges that emerge only after the chair commitment. Clinics that quote a procedure price and then add charges at the chair — for anaesthesia, for moisturiser, for post-procedure regimen, for airport transfer — are clinics that have failed the transit-pricing discipline test. The conversion to USD, CNY, or JPY is patient courtesy rather than transactional figure; the transactional currency is KRW and the FX adjustment runs through the patient's card-issuer. Day-of-procedure negotiation pressure is a vetting red flag; firm package pricing at booking is the editorial standard.

Question 7 — How is the messaging channel structured, and what is the response-time commitment?

The messaging channel — WhatsApp, LINE, WeChat, or KakaoTalk — is the operational thread that connects the transit patient to the clinic across the pre-booking, in-clinic, and post-procedure phases, and the seventh vetting question is how the channel is structured and what response-time commitment the clinic makes. The expected disclosure is the specific channel platform (with the regional-default channel matching the patient's home language), the named coordinator who handles incoming messages, the response-time commitment for clinical questions during the 14-day post-procedure window, and the escalation pathway when the coordinator is unavailable. The editorial standard is a 12 to 24 hour response window for in-protocol clinical questions and a same-day response for genuine in-window concerns; clinics that quote longer windows, that do not name the responding coordinator, or that route through a generic 'reception' inbox are clinics whose post-procedure aftercare relationship is not transit-discipline. Patients should test the channel pre-booking with a substantive vetting question and evaluate the response against the same standard the clinic will be held to post-procedure.

Question 8 — Does the clinic support photo-documented day-7 and day-14 remote reviews?

Photo-documented remote review at days seven and fourteen post-procedure is the clinical-aftercare layer that distinguishes a transit-discipline clinic from a clinic that treats the chair-time as the end of the relationship, and the eighth vetting question is whether the clinic supports this format and how it is administered. The expected disclosure: the clinic provides a structured photo-upload protocol (resolution, lighting, angle standards), a scheduled review by the treating physician (not the coordinator), and a written response with any aftercare adjustment indicated. The editorial standard includes the day-7 and day-14 reviews as part of the package, not as an upsell or optional add-on. Clinics that treat remote review as an extra-cost service have departed from transit-discipline; the day-7 and day-14 review is operationally the only mechanism the transit patient has for clinical follow-up, and a clinic that does not include it is a clinic that has not solved the transit-aftercare problem.

Question 9 — What is the complication pathway if something goes wrong after the patient flies home?

Complications after the transit patient flies home are rare in well-selected protocols, but the ninth vetting question is what pathway the clinic provides when they do occur. The expected disclosure: a clear escalation path through the messaging channel, a treating-physician review of submitted photographs within 12 hours of escalation, a written clinical recommendation, coordination with a destination-country dermatologist if escalation requires in-person review, and a defined financial-responsibility framework for the clinic's part of the recovery (re-treatment if indicated, refund pathway, KHIDI complaint channel as a backstop). The editorial standard is for this pathway to be documented in writing at booking, not improvised when an issue arises. Clinics that decline to commit to a written complication pathway are clinics whose aftercare relationship is not transit-mature; the KHIDI complaint channel is the regulatory backstop but should not be the patient's first recourse, and a clinic without an internal escalation pathway is a clinic that has externalised its aftercare responsibility.

Question 10 — Who handles language coordination in the patient's home language?

Language coordination is the operational layer that turns a clinical consultation into something the international patient can actually use, and the tenth vetting question is who handles the coordination in the patient's home language. The expected disclosure: the coordinator's name, the languages the coordinator works in fluently (not just 'speaks English'), the coordinator's role scope (pre-booking only, in-clinic interpretation, post-procedure messaging, or all three), and the failover when the coordinator is unavailable. The editorial standard is end-to-end coordination by the same individual or a small team — pre-booking, in-clinic interpretation during physician consultation, post-procedure messaging through day 14 — in the patient's home language. Mid-stream handoffs between coordinators with different language combinations introduce miscommunication risk that the transit window cannot absorb. Clinics that use machine translation for clinical communication, that rely on the patient's own English-as-second-language fluency, or that handoff the post-procedure messaging to a different team than the booking team are clinics whose language layer is not transit-disciplined.

Question 11 — Does the clinic have prior-patient transit-case references in the patient's home country?

Prior-patient references are the social-proof layer that the international patient can use to validate the clinic's transit experience, and the eleventh vetting question is whether the clinic has prior transit-case references in the patient's home country who are willing to communicate. The expected disclosure: anonymised or named prior-patient cases (with the prior patient's consent) from the same or similar geography, with a contact pathway through a verified channel (the clinic's messaging channel rather than an unverified email address), and an honest framing of what the prior patient experienced — including any complications or aftercare adjustments. The editorial standard is at least three to five prior transit cases in any major source-country geography (mainland China, Japan, Greater Vietnam, ASEAN, Russia-CIS, EU). A clinic with no prior transit-case references in the patient's region is operating outside its established transit-volume territory, which is not disqualifying but is a fact the patient should weigh; a clinic that declines to provide any prior-patient references at all is a clinic whose transit-volume claim is not verifiable, and the editorial recommendation is to choose differently.

Question 12 — What happens if the patient's flight is delayed or rebooked into a tighter window?

Flight irregularity is the operational variable that the transit patient cannot control, and the twelfth vetting question is what the clinic does when the layover compresses below the protocol's required time envelope. The expected disclosure: a clear policy for in-clinic protocol-depth reduction (if the original booking was for an 8-hour full-course and the layover compresses to 5 hours, the clinic should be able to swap to a 4-hour combined protocol without rebooking friction), a defined refund or credit pathway if the layover compresses below operational minimum, and a same-day rebooking option if the patient extends the layover into an overnight Seoul stay. The editorial standard is a written irregularity policy that the patient receives at booking, not improvised when the disruption occurs. Clinics that quote no policy, that defer to 'we will discuss when it happens', or that hold the booking deposit irrespective of flight irregularity are clinics that have not solved the transit-irregularity problem; the better airport-cluster clinics operate the irregularity policy as a competitive advantage of the transit-discipline format, and the patient should expect to see it in writing before paying.

Frequently asked questions

How long should it take the clinic to respond to a vetting question pre-booking?

Twelve to twenty-four hours for a substantive written response; the response time itself is a vetting signal at least as informative as the content. Clinics that take longer than 48 hours to respond to a vetting question are clinics whose post-procedure messaging-channel responsiveness is likely to be similar.

Can I verify a clinic's KHIDI registration myself?

Yes. The KHIDI public registry of medical-tourism receiving organisations is the verification layer; the registration number takes the form A-YYYY-MM-DD-NNNNN and should match the clinic's stated number. A clinic without a KHIDI registration is operating outside the medical-tourism regulatory framework regardless of clinical practice quality.

What MFDS licence am I checking on the bio-active product?

The MFDS licence is on the cell-processing manufacturing facility that produces the exosome, growth-factor, or conditioned-media product — not on the clinic itself. The clinic should provide the manufacturer name and the licence reference; you can verify the manufacturer against the MFDS English portal's licensed-manufacturer registry.

What credentials should the treating physician have for transit-window stem cell IV?

Aesthetic Medicine Specialist or Medical Director designation, a Korean medical licence number, at least ten years of independent practice, and documented experience with exosome and growth-factor protocols specifically. A junior-trainee physician operating an airport-cluster transit clinic is a substantive vetting concern.

Is package pricing always better than per-add-on pricing?

For transit windows, yes. Package pricing in KRW with line items broken out is the editorial standard because it eliminates chair-time negotiation pressure and lets the patient confirm the all-in cost at booking. À la carte pricing introduces surprise-charge risk that the transit format cannot absorb.

What is the editorial response-time standard for the messaging channel post-procedure?

Twelve to twenty-four hours for in-protocol clinical questions during the 14-day post-procedure window; same-day response for genuine in-window concerns. A clinic that does not commit to this window in writing at booking is a clinic whose post-procedure aftercare relationship is not transit-disciplined.

Do all airport-cluster clinics support day-7 and day-14 remote reviews?

No, and this is one of the most informative vetting distinctions. The transit-discipline clinics include photo-documented day-7 and day-14 review by the treating physician as part of the package; the clinics that treat remote review as an extra-cost service or that decline to commit to the schedule have not solved the transit-aftercare problem.

What is the patient's recourse if a post-procedure issue is not handled well?

The internal escalation pathway through the messaging channel is the first recourse; the KHIDI complaint channel is the regulatory backstop for KHIDI-registered receiving organisations. A clinic that lacks an internal escalation pathway has externalised its aftercare responsibility to the regulator, which is not the editorial standard.